IP Library › Patent Application 10594641
Patent Application
App. No. 10/594,641

Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/594,641
Abstract

Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing or treating type 1 diabetes. The methods comprise determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF, determining whether the compound inhibits development of type 1 diabetes.

Claims (27)

1 : A method of treating a mammal having type 1 diabetes or at risk for type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an agent that inhibits a macrophage migration inhibitory factor (MIF) in the mammal, wherein the agent is a polypeptide or a polynucleotide.

2 : The method of claim 1 , wherein the agent comprises a binding site of an antibody that binds specifically to the MIF.

3 : The method of claim 2 , wherein the agent is an antibody.

4 : The method of claim 1 , wherein the agent is an aptamer that binds specifically to the MIF.

5 : The method of claim 1 , wherein the agent inhibits expression of the MIF.

6 : The method of claim 5 , wherein the agent is an antisense nucleic acid or mimetic specific for MIF mRNA in the mammal.

7 : The method of claim 5 , wherein the agent is a ribozyme nucleic acid or mimetic specific for MIF mRNA in the mammal.

8 : The method of claim 5 , wherein the agent is an inhibitory RNA or mimetic specific for MIF mRNA in the mammal.

9 : The method of claim 1 , wherein the mammal has or is at risk for having diabetes, impaired glucose intolerance, stress hyperglycemia, metabolic syndrome, and/or insulin resistance.

10 : The method of claim 1 , wherein the mammal is a rodent.

11 : The method of claim 1 , wherein the mammal is a human.

12 - 13 . (canceled)

14 : A method of evaluating whether a compound is useful for preventing or treating type 1 diabetes, the method comprising

(a) determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF,

(b) determining whether the compound inhibits development of type 1 diabetes.

15 : The method of claim 14 , wherein step (b) is performed by evaluating the effect of the compound on proliferation of splenic lymphocytes in the mammal.

16 : The method of claim 14 , wherein the compound is a protein.

17 : The method of claim 16 , wherein the protein comprises an antibody binding site.

18 : The method of claim 14 , wherein the compound is a nucleic acid or mimetic.

19 : The method of claim 18 , wherein the nucleic acid or mimetic is an antisense, a ribozyme, an aptamer, or an interfering RNA.

20 : The method of claim 14 , wherein the compound is an organic molecule less than 1000 Dalton.

21 . (canceled)

22 : A kit comprising

(a) a pharmaceutical composition comprising the agent used to inhibit MIF in claim 1 , and

(b) instructions for administering the composition to the mammal,

wherein the mammal has type 1 diabetes or is at risk for type 1 diabetes.

23 - 25 . (canceled)